HomeAI · summaries
Storia in 8 fonti
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
Gilead's FDA-approved Bixlenvo (BIC/LEN), a grain-of-rice-sized once-daily HIV pill, targets virologically suppressed patients & those with NRTI resistance.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
- ·
fiercepharma.com
Gilead christens Bixlenvo with FDA nod for new HIV treatment combo tablet
Some 20 years after helping introduce the first once-daily single tablet HIV regimen, Gilead Sciences has crossed the regulatory finish line with a new oral treatment option in…
